

861292965

B2

24



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11) Publication number.

0 200 322

A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86301989.9

(51) Int. Cl. 4: C 07 D 209/40

C 07 D 401/14, C 07 D 413/14
A 61 K 31/40

(22) Date of filing: 18.03.86

NEW 1-(HETERO)ARYL-3-PIPERAZINO OR TETRAHYDROPIPERAZYL-
1H-INDOLE COMPS. ARE DOPAMINERGIC AND 5-HT
ANTAGONISTS USEFUL FOR TREATING PSYCHOSIS

(A) METAPE B

(30) Priority: 10.04.85 GB 8509164


(71) Applicant: H. LUNDBECK A/S

Ottileavej 7-9
DK-2500 Kobenhavn-Valby(DK)(43) Date of publication of application:
05.11.86 Bulletin 86/45(72) Inventor: Perregaard, Jens Kristian
54. Pyttervaenget
DK-3650 Oestlykke(DK)(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE(74) Representative: Wilkinson, Stephen John et al,
c/o Stevens, Hewlett & Perkins 5 Quality Court Chancery
Lane
London WC2A 1HZ(GB)

1557

(54) Heterocyclic compounds.


(55) Indole derivatives of the general formula:



wherein R is phenyl, optionally substituted with halogen, lower alkyl or trifluoromethyl, or a hetero aromatic group, such as 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-thiazol, 2-oxazol, 2-imidazole, 2-pyridyl, 3-pyridyl or 4-pyridyl; R¹ is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, lower alkylthio, trifluoromethyl, lower alkylsulfonyl, amino, lower alkylamino or lower di-alkylamino;

"A" is nitrogen or carbon, and the dotted line indicates - when A is carbon - an optional bond.

R² is hydrogen, cycloalkyl, lower alkyl or lower alkenyl, optionally substituted with one or two hydroxy groups, any hydroxy group present being optionally esterified with an aliphatic carboxylic acid radical having from two to twenty-four carbon atoms inclusive.

or R² is the group

wherein "n" is an integer of 2-6;

X is oxygen or sulfur, or >C = X may constitute the group >CH = when Y is =N- or =CH-;

Y is oxygen, sulfur, CH, or N R³, where R³ is hydrogen or lower alkyl, lower alkenyl or a cycloalkylmethyl group, said "cycloalkyl" having from three to six carbon atoms inclusive;Z is -(CH₂)_m-, "m" being 2 or 3, or Z is -CH=CH- or 1,2-phenylene optionally substituted with halogen or trifluoromethyl, or Z is -CO(or SICH₂)-;U is nitrogen or carbon, provided that when R¹ is chloro, A is nitrogen and R² is methyl or cyclohexyl, R may not be phenyl; as well as their pharmaceutically acceptable acid addition salts, are described as having pronounced activity in the treatment of psychoses.

Moreover, methods for the preparation of the indole derivatives of Formula 1 are described.

EP 0 200 322 A1

86292965

10. .986

phn/rr


0200322

HETEROCYCLIC COMPOUNDS

The present invention relates to novel indole derivatives which have interesting pharmacodynamic effects indicating pronounced activity in the treatment of psychic disorders, especially psychoses and, at the same time, a low degree of undesired side effects.

5 Moreover, the invention relates to methods for the preparation of said indole derivatives, pharmaceutical compositions containing same, and methods for the treatment of psychic disorders, especially psychoses, by administering a therapeutically active amount of one of said derivatives to a living animal body, including human beings.

10 The novel indole derivatives of the present invention are represented by the following formula:



0200322

2


wherein R is phenyl, optionally substituted with halogen, lower alkyl or trifluoromethyl, or a hetero aromatic group, such as 2-thienyl, 3-thienyl, 2-furoyl, 3-furoyl, 2-thiazol, 2-oxazol, 2-imidazole, 2-pyridyl, 3-pyridyl or 4-pyridyl;

R¹ is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, lower alkylthio, trifluoromethyl, lower alkylsulfonyl, amino, lower alkylamino or lower di-alkylamino;

"A" is nitrogen or carbon, and the dotted line indicates - when A is carbon - an optional bond;

R² is hydrogen, cycloalkyl, lower alkyl or lower alkenyl, optionally substituted with one or two hydroxy groups, any hydroxy group present being optionally esterified with an aliphatic carboxylic acid radical having from two to twenty-four carbon atoms inclusive,

or R² is the group



wherein "n" is an integer of 2-6;

X is oxygen or sulfur, or >C=X may constitute the group ^CH= when Y is =N- or =CH-;

Y is oxygen, sulfur, CH_2 or N R³, where R³ is hydrogen or lower alkyl, lower alkenyl or a cycloalkylmethyl group, said "cycloalkyl" having from three to six carbon atoms inclusive;

Z is $-(\text{CH}_2)_m -$, "m" being 2 or 3, or Z is -CH=CH- or 1,2-phenylene optionally substituted with halogen or trifluoromethyl, or Z is -CO(or S)CH₂-;

U is nitrogen or carbon,

provided that when R¹ is chloro, A is nitrogen and R² is methyl or cyclohexyl, R may not be phenyl;

as well as their pharmaceutically acceptable acid addition salts.

In the past, several indole derivatives being substituted at the nitrogen atom with a carboxylic acid radical have been found to possess analgetic and anti-inflammatory properties. Recently it was suggested in German OLS No. 2811031 that also indoles having a phenylsubstituent at the nitrogen atom might have the desired analgetic or antiinflammatory effects, but no data were given for the 1-phenyl-5-chloro-3-methylpiperazine-indole or 1-phenyl-5-chloro-3-cyclohexyl-piperazine-indole actually disclosed in the specification. We have prepared the first-mentioned of these compounds (Lu 23-015) and found that it was without interesting effects in the pharmacological testing carried out in our laboratories.

1559

86292965

3

In European Patent Application No. 80401005.6 some derivatives of tetrahydro-pyridinyl-indoles having at the 1-position either hydrogen or alkyl (1-3 C-atoms), were described as being neuroleptics. The pharmacological data given in the specification, however, indicate only weak to moderate neuroleptic activity.

5 We have prepared one of these compounds, 5-chloro-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyrid-4-yl)indol (Lu 23-143) and found that it was almost inactive compared with the compounds of Formula I.

10 It has now surprisingly been found that the novel indole derivatives of Formula I are potent dopaminergic antagonists in pharmacological tests, both *in vivo* and *in vitro*, as compared with wellknown neuroleptics commonly used in the treatment of psychoses; and especially very long-lasting effects - up to several days - were observed with many of the compounds of Formula I. Additionally, most of the indoles of Formula I are strong 5-HT antagonists both peripherically and centrally, which is considered to be important for the treatment of psychic disorders or 15 cardiovascular diseases.

20 The terms lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl designate such groups having from one to four carbon atoms inclusive. Exemplary of such groups are methyl, ethyl, *n*-propyl, iso-propyl, *n*-butyl, sec.butyl, methoxy, ethoxy, propoxy, butoxy, methylthio, ethylthio, propylthio, methylsulfonyl, ethylsulfonyl, or the like.

25 The term lower alkenyl designates alkenyl groups having from two to four carbon atoms, for example ethenyl, 1-propenyl, 2-butenyl, or the like.

This invention also includes pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids. Such salts are easily prepared by methods known to the art.

1560

86292965

The base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly.


Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanesulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the classical method of double decomposition of appropriate salts, which is wellknown to the art.

The compounds of Formula I as well as the pharmaceutically acceptable acid addition salts thereof may be administered both orally and parenterally, for example in the form of tablets, capsules, powders, syrups or solutions for injection.

Of the indoles of Formula I, those wherein R^1 is chlorine, fluorine, trifluoromethyl, methyl, nitro or amino in the 5-position, R is phenyl substituted with fluorine in the 4'-or the 2'-position, R^2 is methyl, hydroxyethyl or 3-hydroxypropyl, and A is as defined above, have shown especially favourable effects in the pharmaceutical testing, and also have few undesired side effects.

The invention moreover relates to a method for the preparation of the novel indoles of Formula I, which comprises

a) reacting an indole derivative of the following formula:




1561

11

86292965


w herein R¹ and R are as defined above, with a 4-piperidone of the formula:



wherein R² is as defined above,

or

5 b) reducing a compound of the following formula:




III

wherein R¹, R and R² are as defined above,

or

c) reacting a compound of the following formula:



IV


10 wherein R¹, R² and A are as defined above, with a compound of formula:



wherein R is as defined above and "hal" is halogen, in the presence of a metal catalyst,

or

15 d) reacting a compound of the following formula:



V


1562

86292965

6
wherein R^1 , R and A are as defined above, with a lower alkyl halide or an epoxide of formula $H_2C-\overset{\text{O}}{\text{C}}-\text{CH R}$ wherein R is hydrogen, methyl or ethyl,

or

e) reducing a compound of the following formula:




VI

wherein R^1 , R and A are as defined above and R^4 is hydrogen, lower alkyl (1-3 C-atoms) or lower alkoxy (1-3 C-atoms),


or

f) heating a compound of the following formula:



VII


10
wherein R^1 and R are as defined above, with a piperazine of formula:



wherein R^2 is as defined above,

or

15
g) reducing a compound of the following formula:



VIII

1563

86292965

7

0200322


5

wherein R^1 , R and R^2 are as defined above, with a suitable reducing agent, whereupon the indole of Formula I is isolated in the form of the free base or a pharmaceutically acceptable acid addition salt thereof, and if the group R^2 contains one or two hydroxyl groups, if desired, acylating such a hydroxy group with a reactive derivative of an aliphatic carboxylic acid having from two to twenty-four carbon atoms, and isolating the ester formed as the free base or a pharmaceutically acceptable acid addition salt thereof.

10

In method a) the reaction is performed under strong acidic conditions by heating. Trifluoroacetic acid or HCl in ethanol are preferred as acid catalysts. The starting compounds of Formula II are conveniently prepared according to procedures described in the litterature, e.g. by reduction of R substituted isatins or oxindoles by a method described by H. Sirowej et al. in Synthesis 1972, 84, according to the following reaction scheme:

15




20

Isatins and oxindoles are prepared by a Fiedel-Craft ring closure under standard conditions from N -oxalylchloro- or N -(2-chloroacetyl) diphenylamines respectively. The compounds of Formula II may alternatively be prepared by arylation of N -unsubstituted indoles according to the method described by M.A. Khan and E.K. Rocha, Chem. Pharm. Bull. 25 (11), 3110-3114 (1977).

1564

An alternative way of obtaining the intermediates of Formula II is that from an indoxyl-2-carboxylic ester as outlined below:




In method b) the reduction is preferably carried out at low hydrogen pressures (3 atm.) in the presence of platinum or palladium on carbon black.

In method c) the arylation is preferably carried out at about 160-210°C in aprotic polar solvents as e.g. N-methyl-2-pyrrolidone or hexamethylphosphoric triamide with K_2CO_3 as base and copper as a catalyst.

In method e) the reduction is preferably carried out with $LiAlH_4$ in THF or diethylether or with diborane in THF.

Method f) is a two step procedure in which compound VII first is decarboxy-alkylated in the presence of an inorganic salt as e.g. $LiCl$ or $MgCl_2$ in a polar solvent as e.g. diglyme, hexamethylphosphoric triamide or N-methyl-2-pyrrolidone at elevated temperatures (120-150°C). Finally, the appropriate piperazine is added and the temperature raised to about 200°C and kept there until the corresponding indoxyle has disappeared according to TLC analysis. The compounds of Formula VII are conveniently prepared according to the procedures reported by P.C. Unangst and M.E. Carethers, J.Heterocyclic Chem. 21, 709 (1984).

In method g) diborane in THF is conveniently used as a reducing agent. The compounds of Formula VIII are prepared from the corresponding R-substituted isatins according to the following reaction scheme:



The methods of the invention shall be illustrated in the following by some examples, which may not be construed as limiting:

EXAMPLE I

(Method a)

5 1-(4'-Fluorophenyl)-5-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole hydrochloride (Lu 20-089).

10 1-(4'-fluorophenyl)-5-methyl-1H-indole (4.5 g) and 1-methyl-4-piperidone (5 g) were dissolved in 25 ml of acetic acid and added dropwise to 50 ml of trifluoroacetic acid kept almost at the boiling point. The mixture was gently refluxed for another 1/2 h. Excess trifluoroacetic acid was evaporated and the reaction mixture was added to 50 ml of 6 M HCl and 50 ml of ether. The precipitated title compound was filtered off and dried. Yield: 3.1 g (43%). M.p. 262-266°C.

15 In a corresponding manner the following tetrahydropyridin-4-ylindoles were prepared:

5-Fluoro-1-(4'-fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, hydrochloride. (Lu 21-018). M.p. 256°C.

1-(4'-Fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoromethyl-1H-indole, oxalate. (Lu 21-120). M.p. 228-229°C.

20 1-(4'-Fluorophenyl)-5-nitro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole (Lu 22-135). M.p. 168-170°C.

1-(3'-Fluorophenyl)-5-nitro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, maleate. (Lu 24-004). M.p. 216-217°C.

25 1-(2'-Fluorophenyl)-5-nitro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, maleate. (Lu 24-003). M.p. 208°C.

3-(1-(2-Hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-(4'-trifluoromethylphenyl)-1H-indole, fumarate. (Lu 24-012). M.p. 174-175°C.

1-(4'-Fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, hydrochloride. (Lu 23-083). M.p. 268-270°C.

30 1-(4'-Fluorophenyl)-5-nitro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, maleate. (Lu 23-133). M.p. 204-205°C.

86292965

1566

5-Chloro-1-(4'-fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, hydrochloride. (Lu 23-146). M.p. 280-282°C.

5-Chloro-1-(4'-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole. (Lu 23-147). M.p. 105-107°C.

5-1-(4'-fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole. (Lu 23-150). M.p. 151-152°C.

5-1-(4'-Fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoromethyl-1H-indole. (Lu 23-155). M.p. 128-130°C.

5-1-(4'-Fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoromethyl-1H-indole. (Lu 23-156). M.p. 140-141°C.

5-Fluoro-1-(4'-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole. (Lu 23-159). M.p. 75-77°C.

5-Fluoro-1-(4'-fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, oxalate. (Lu 23-160). M.p. 180-184°C.

5-Fluoro-1-(4'-fluorophenyl)-3-(1-(2-propyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, fumarate. (Lu 23-167). M.p. 190-195°C.

5-(4'-Fluorophenyl)-3-(1-(3-hydroxypropyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoromethyl-1H-indole. (Lu 23-171). M.p. 159-161°C.

5-Fluoro-1-(4'-fluorophenyl)-3-(1-(3-hydroxypropyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, oxalate. (Lu 23-175). M.p. 173-175°C.

EXAMPLE 2

(method b)

5-(4'-Fluorophenyl)-3-(1-methyl-4-piperidyl)-5-trifluoromethyl-1H-indole, oxalate. (Lu 21-131).

Compound Lu 21-120, oxalate (2.5 g) is dissolved in ethanol (200 ml), and PtO₂ (0.2 g) is added. Hydrogenation is continued for 3h at 3 atm. The catalyst was then filtered off, ethanol evaporated and the title compound crystallized from acetone/ether. Yield: 1.2 g (48%). M.p. 251-252°C.

11

0200322

In a corresponding manner were also prepared:

1-(4'-Fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-4-piperidyl)-1H-indole.
(Lu 23-086). M.p. 174-175°C.

5 1-(4'-Fluorophenyl)-3-(1-(1-pyrrolidin-2-onylethyl)-4-piperidyl)-5-trifluoromethyl-
 1H-indole, fumarate. (Lu 23-158). M.p. 240-241°C.

5-Chloro-1-(4'-fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-4-piperidyl)-
 1H-indole, maleate. (Lu 23-174). M.p. 155-160°C.

EXAMPLE 3

(Method c)

10 3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1-pyridin-3-yl-1H-indole.
(Lu 24-016).

15 3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole (4.5 g), 3-bromo-
 pyridin (6.0 g), CuBr (4.5 g) and K_2CO_3 (8.0 g) were heated under stirring at
 160°C for 2.5 h. After cooling the reaction mixture was poured into diluted
 NH_4OH (500 ml) and extracted with ethyl acetate (2 x 300 ml). The combined
 organic phases were dried ($MgSO_4$) and the solvent evaporated. The title
 compound was obtained by recrystallization from acetone. Yield: 3.4. g (58%).
 M.p. 175-177°C.

In a corresponding manner were also prepared:

20 3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1-pyridin-2-yl-1H-indole.
(Lu 24-015). M.p. 134°C.

3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1-(2-thiazolo-1H-indole).
(Lu 24-022). M.p. 204-206°C.

25 5-Chloro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1-(3-thienyl)-1H-indole,
 maleate. (Lu 24-001). M.p. 168-170°C.

3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1-(2-thienyl)-1H-indole,
 maleate. (Lu 24-014). M.p. 206-208°C.

1568

86292965

0200322

12

EXAMPLE 4

(methods c and e)

5-Chloro-1-(4'-fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, hydrobromide. (Lu 22-117).

5-Chloro-3-(1-carbethoxy-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole (10 g), 1,4-fluoroiodobenzene (15 g), CuBr (10 g) and K_2CO_3 (15 g) in HMPA (50 ml) were heated (180-200°C) while stirring for 3h. After cooling the reaction mixture was poured into H_2O (1 ltr.) and ethylenediamine (100 ml). The crude product was obtained by extraction twice with ether/ethyl acetate (2:1). The combined organic phases were dried ($MgSO_4$) and the solvents were evaporated. The pure 5-chloro-1-(4'-fluorophenyl)-3-(1-carbethoxy-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole was obtained by column chromatography on silica gel (eluent 30% ether in dichloromethane). Yield: 8.9 g (68%). M.p. 120-122°C. The carbethoxy compound then obtained (3 g) was dissolved in dry THF (50 ml) and $LiAlH_4$ pellets (2 g) were added. The mixture was refluxed for 1h, cooled and H_2O/THF added to destroy excess $LiAlH_4$. The precipitate was filtered off and THF evaporated. The remaining oil was dissolved in acetone and the title compound precipitated as a hydrobromide salt. Yield: 2.4 g (75%). M.p. 285°C.

In a corresponding manner were also prepared:

5-Chloro-1-(4'-fluorophenyl)-3-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, hydrobromide. (Lu 22-134). M.p. 285-286°C.

5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1-(2-thiazolo)-1H-indole, fumarate. (Lu 24-013). M.p. 190-194°C.

EXAMPLE 5

(method d)

5-Fluoro-2-(4'-fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, oxalate. (Lu 21-046)

5-Fluoro-1-(4'-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole (2g) prepared as described in Example 1; 1-chloroethyl-2-imidazolidinon (2 g), K_2CO_3 (3 g) and a small crystal of KI were refluxed in methyl isobutyl ketone (50 ml) for 16 h. The reaction mixture was poured into H_2O and CH_2Cl_2 (200 ml) was added. The organic phase was separated, dried ($MgSO_4$) and the solvents evaporated. The crude product was dissolved in acetone and precipitated as an oxalate salt. Yield: 1.2 g (36%). M.p. 186-189°C.

1569

86292965

13

0200322

In a corresponding manner the following indoles were prepared:

1-(4'-Fluorophenyl)-3-(4-(2-imidazolidinon-1-ylethyl)-1-piperazino)-5-trifluoromethyl-1H-indole, dihydrobromide. (Lu 23-001). M.p. 262-263°C.

5 1-(4'-Fluorophenyl)-3-(4-(1-pyrrolidin-2-onylethyl)-1-piperazino)-5-trifluoromethyl-1H-indole. (Lu 22-133). M.p. 224-227°C.

1-(4'-Fluorophenyl)-5-nitro-3-(1-pyrrolidin-2-onylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, hydrochloride (Lu 23-024). M.p. 263-265°C.

10 1-(4'-Fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, hydrochloride. (Lu 23-075). M.p. 259-262°C.

1-(4'-Fluorophenyl)-5-nitro-3-(1-(2-oxazolidinon-1-ylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, maleate. (Lu 23-134). M.p. 128-130°C.

15 1-(4'-Fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole. (Lu 23-142). M.p. 177-179°C.

5-Chloro-1-(4'-fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole. (Lu 23-148). M.p. 138-140°C.

1-(4'-Fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoromethyl-1H-indole. (Lu 23-157). M.p. 164-165°C.

1-(2'-Fluorophenyl)-3-(1-(2-imidazolidinon-1-ylethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole, maleate. (Lu 24-024). M.p. 200°C.

10 EXAMPLE 6

(Method e)

1-(4'-Fluorophenyl)-3-(1-pyrrolo-2-ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoro-methyl-1H-indole, maleate. (Lu 23-172).

1-(4'-Fluorophenyl)-3-(1-pyrrolo-2-aceto)-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoro-methyl-1H-indole (2.5g) was refluxed with LiAlH_4 (1g) in dry THF (50ml) for 1.5h. After cooling $\text{H}_2\text{O}/\text{THF}$ was added to destroy excess of LiAlH_4 . The precipitate was filtered off and THF evaporated. The remaining oil was dissolved in 2-propanol and the title compound precipitated as a maleate. Yield: 1.3 g (42%). M.p. 194-

195°C.

1570

86292965

14

0200322

in a corresponding manner were also prepared:

1-(4'-Fluorophenyl)-3-(1-(2-methyl-1-imidazole-2-ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoromethyl-1H-indole, difumarate. (Lu 23-173). M.p. 189-191°C.

1-(4'-Fluorophenyl)-3-(1-(1-imidazole-2-ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-5-trifluoromethyl-1H-indole, dimaleate. (Lu 24-002). M.p. 165-167°C.

EXAMPLE 7

(method f)

1-(4'-Fluorophenyl)-3-(4-methylpiperazino)-5-trifluoromethyl-1H-indole, dihydrochloride. (Lu 21-123).

2-Carboxymethyl-1-(4'-fluorophenyl)-5-trifluoromethylindolin-3-on (15 g) and $MgCl_2 \cdot 6 H_2O$ (30 g) in HMPA (100 ml) were heated under N_2 at 120-140°C for 1 h and finally at 150°C for another 1/2 h. 1-Methylpiperazin (25 ml) was added and the mixture was refluxed under N_2 at an oil bath temperature of 200°C for 16 h. The mixture was cooled and poured into 1 ltr. of H_2O and extracted with ether (3 x 200 ml). The combined ether extracts were washed with 0.5 M HCl (3 x 300 ml). The acidic H_2O phase was made alkaline and reextracted with ether (2 x 200 ml). The combined organic phase was dried ($MgSO_4$) and the ether evaporated. The remaining oil was dissolved in acetone and the title compound precipitated as a dihydrochloride. Yield: 6.7 g (35%). M.p. 245-247°C.

In a corresponding manner the following 3-piperazinoindoles were prepared:

1-(4'-Fluorophenyl)-3-(4-(2-hydroxyethyl)-piperazino)-5-trifluoromethyl-1H-indole. (Lu 21-152). M.p. 164°C.

1-(4'-Fluorophenyl)-3-piperazino-5-trifluoromethyl-1H-indole. (Lu 21-153). M.p. 163-170°C.

1-(4'-Fluorophenyl)-3-(4-isopropyl-piperazino)-5-trifluoromethyl-1H-indole, dihydrochloride. (Lu 23-016). M.p. 278-280°C.

5-Chloro-3-(4-methylpiperazino)-1-phenyl-1H-indole. (Lu 23-015). M.p. 174-175°C.

1871

EXAMPLE 8
(method g)

15

0200322

1-(4'-Fluorophenyl)-5-methyl-3-(1-methyl-4-piperidyl)-1H-indole, hydrobromide. (Lu 21-037).

5 To 14 g of Mg turnings was added 4-chloro-1-methylpiperidine (35 g) in dry THF (500 ml). The mixture was refluxed for 1 hour and filtered under N_2 into an ice cooled solution of 1-(4'-fluorophenyl)-5-methylisatin (60 g) in dry THF (500 ml). The mixture was heated to reflux and poured into H_2O (1 ltr.) saturated with NH_4Cl and extracted with ether (2 x 300 ml). The combined organic phases were dried ($MgSO_4$), the ether evaporated yielding 48.5 g (58%) of 1-(4'-fluorophenyl)-2-hydroxy-5-methyl-3-(1-methyl-4-piperidyl)indolin-2-on. M.p. 177-179°C. To a suspension of $LiAlH_4$ (1 g) in dry THF (100 ml) was added 2.5 g of the above prepared indolin-2-on. The mixture was refluxed for 1 hour, excess of $LiAlH_4$ destroyed by addition of H_2O / THF, and filtered; and 2 M HCl (500 ml) was added to the filtrate and gently heated. The H_2O phase was made alkaline and the product extracted with ether (2 x 300 ml). The combined ether phases were dried ($MgSO_4$) and the ether evaporated. The remaining oil was dissolved in acetone and 1-(4'-fluorophenyl)-5-methyl-3-(1-methyl-4-piperidyl)indolin-2-on was precipitated as an oxalate. Yield: 2.0 g (66%). M.p. 222°C. To a solution of B_2H_6 in THF (100 ml) kept under N_2 at 0°C was added 11.0 g of the oxalate salt prepared as above. The mixture was heated slowly to 50°C and kept there for 2 hours. It was finally poured onto ice (1 ltr.) and extracted with ether (2 x 200 ml). The combined ether phases were dried ($MgSO_4$) and the ether evaporated. The remaining oil was dissolved in 2-propanol and the title compound precipitated as a hydrobromide salt. Yield: 3.7 g (36%). M.p. 254-256°C.

EXAMPLE 9

5-Amino-1-(4'-fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole, fumarate. (Lu 23-149)

1-(4'-Fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole (Lu 22-135) (10 g) in 90% ethanol (150 ml) was heated to reflux and dil. HCl (2 ml) and Fe-powder (5 g) were added within 0.5 hour. Reflux was continued for another hour. The reaction mixture was filtered, cooled down and subsequently poured into 1 litre of NH_4OH and extracted with ethyl acetate (2 x 400 ml). The combined organic phases were dried ($MgSO_4$) and the solvent evaporated. The remaining oil was purified by column chromatography on silica gel (eluted with ethyl acetate/methanol 1:1 containing 2% of triethylamine). The title compound was finally precipitated as a fumarate from ethanol/acetone (1:1). Yield 4.2 g (1572) (34%). M.p. 128-134°C.

0200322

16

EXAMPLE 10

1-(4'-Fluorophenyl)-3-(4-(2-(pyrrolidin-2-thion-1-yl)-ethyl)-1-piperazino)-5-trifluoromethyl-1H-indole (Lu 23-018).

The pyrrolidonyl indole derivative (Lu 22-133) (2.8 g) prepared in Example 4 and p-methoxyphenylthionophosphine sulfide dimer (2.0 g) (Lawesson reagent) were heated in HMPA (25 ml) at 110 °C for 1 hour. The reaction mixture was poured into H₂O (500 ml) and K₂CO₃ (10 g) added. The product was extracted with ether containing 10% of ethyl acetate (2 x 200 ml). The combined organic phases were dried (MgSO₄), the solvents evaporated and the resulting crystalline product was recrystallized from ethanol yielding 2.1 g (73%) of the title compound. M.p. 199-201 °C.

EXAMPLE 11

3-(4-(1-Acetoxyethyl)-1-piperazino)-1-(4'-fluorophenyl)-5-trifluoromethyl-1H-indole. (Lu 23-161).

1-(4'-Fluorophenyl)-3-(4-(2-hydroxyethyl)-1-piperazino)-5-trifluoromethyl-1H-indole (Lu 21-152) (5 g) was heated to reflux in acetone (50 ml). Acetylchloride (2 ml) was added slowly. Refluxing was continued for 1.5 h. The solvent was evaporated and the remaining oil was extracted with CH₂Cl₂ (2 x 200 ml) from NH₂OH at Ph 10. The combined organic phases were dried (MgSO₄) and the solvent evaporated. The title compound precipitated from ether. Yield: 3.7 g (72%). M.p. 129-131 °C.

In a corresponding manner the following esterified indole derivatives were prepared:

3-(4-(1-decanoyloxyethyl)-1-piperazino)-1-(4'-fluorophenyl)-5-trifluoromethyl-1H-indole. (Lu 23-162). M.p. 71-73 °C.

1-(4'-Fluorophenyl)-3-(4-(1-oleyoxyethyl)-1-piperazino)-5-trifluoromethyl-1H-indole, dihydrochloride. (Lu 23-163). M.p. 158-162 °C.

9 - 1573

86292965

The compounds of Formula I were tested according to reliable and well recognized pharmacological tests as follows:

1. Methylphenidate antagonism

The inhibiting effect of test substances on the methylphenidate-induced gnawing in mice is determined as described by Pedersen and Christensen (1972).

The test substance is given i.p. in different doses, while methylphenidate is given s.c. in the dose 60 mg/kg, 1/2, 2 or 24 hours after injection of test substance. Per dose of the test substance is used 3 x 2 mice (♂, 18-25 g). The results are given in fractions: 0/3, 1/3, 2/3 and 3/3, where 0, 1, 2 and 3 are the number of pairs, which has not been gnawing on receipt of the test substance.

Ref.:

Pedersen, V. and Christensen, A.V.: Acta pharmacol. et toxicol. 31, 488-496, 1972.

2. Catalepsy

Evaluation of catalepsy is made according to Arnt (1983). The rat is placed on a vertical wire mesh (mesh diameter 12 mm) and considered as cataleptic if it remains immobile for more than 15 seconds. The number of cataleptic rats in each dose group is determined every hour, 1-6 hours and 24 hours following peroral administration of test compound. The maximal numbers of cataleptic rats in each of at least 3 dose groups, each consisting of at least 4 rats, is recorded. These numbers are used for calculation of ED₅₀ values by log-probit analysis.

Ref.:

Arnt, J.: European J. Pharmacol. 95, 47-55, 1983.

3. Quipazine inhibition

Quipazine and a number of other compounds, which increase 5-HT₂ receptor activity in the CNS, induce a characteristic rapid shake (twitch) of the head. This response is inhibited by 5-HT₂ receptor antagonists (Vetulani et al. 1980, Arnt et al. 1984).

86292965

The test compound or saline is injected subcutaneously 2 hours before subcutaneous injection of quipazine hydrochloride (15 µmol/kg). At least 3 dose groups, each consisting of at least 4 rats, are used. The rats are individually placed in

0200322

18

observation cages (12 x 25 cm) and the number of head twitches are counted 30-40 min after quipazine administration. Inhibition of head twitches is expressed in per cent of the number of head twitches in the control group. ED50 values are calculated by log-probit analysis.

5

Ref.:

Vetulani, J., B.B. Beduarczyk, K. Reichenberg and A. Rokosz: Neuropharmacology 19, 155-158, 1983.

Arnt, J., J. Hyttel and J.-J. Larsen: Acta pharmacol. et toxicol. 55, 363-372, 1984.

10

4. ^3H -spiroperidol bindings

The affinity of compounds to dopamine (DA) D-2 receptors and serotonin₂ (5-HT₂) receptors was determined by in vitro receptor binding technique. Binding of ^3H -spiroperidol to DA D-2 receptors in rat striatal membranes and to 5-HT₂ receptors in rat cortical membranes was determined as described in detail by

15

Arnt et al. (1984).

Ref.:

Arnt, J., J. Hyttel and J.-J. Larsen: Acta pharmacol. et toxicol. 55, 363-372, 1984.

86292965

1575

Pharmacology of Indoles

Compound No.	MePh Antg.	Catalep.		Qvipaz. inh.	^3H -Spiroperidol bindings	
		ED50(ip) ($\mu\text{mol/kg}$)	ED50(po) ($\mu\text{mol/kg}$)		ED50(sc) ($\mu\text{mol/kg}$)	DA-2 receptors
						$IC_{50}/10^{-9}\text{M}$
Lu 20-089	0.18	0.43	6.5	0.12	0.34	1.8
Lu 21-018	0.58	2.00	>6.9	0.15	0.74	3.6
Lu 21-037	2.10					
Lu 21-046	48.1			0.23		
Lu 21-120	0.08	0.32	0.35	0.03	0.61	3.1
Lu 21-123	0.09	0.08	0.62	0.035	1.7	6.7
Lu 21-131	0.60	0.59	2.2			
Lu 21-152	0.11	0.17	0.28	0.023	2.8	7.4
Lu 21-153	2.0	7.1	16.0	0.37	3.7	6.7
Lu 22-117	0.06	0.09*	>0.37*	.052	1.2	0.66
Lu 22-133	0.82	0.66*	1.7*	0.15		1.9
Lu 22-134	1.7	2.7*	>2.7*	2.5	5.3	
Lu 22-135	0.10	0.078	>0.89*	0.009	1.1	1.9
Lu 23-001	0.22	1.2	2.6	0.047	6.6	18
Lu 23-011	0.12*	0.55	>1.8	0.041		0.36
Lu 23-015	8.8	12.0	>15	0.062	12.0	3.9
Lu 23-018	53.0	1.2	2.9			
Lu 23-024	0.65	6.8*	>10*			5.3
Lu 23-075	19*			0.18		
Lu 23-083	1.3*	9.4	>14	0.15	1.8	
Lu 23-086	>98*			0.036	42	2.9
Lu 23-133	18*	11.0	>11			5.9
Lu 23-134	9.0*	1.1	>8.8		2.8	15
Lu 23-142	2.6*					6.7
Lu 23-143	72.0*	>18*	>18*	4.5		
Lu 23-146	0.73*	1.0*				
Lu 23-147	>99*					
Lu 23-148	>91*		86292965			
Lu 23-149	0.45*					
Lu 23-150	0.07*	0.21			4.7	10

20

0200322

Compound No.	MePh Antg.	Catalep.		Ovipaz. inh.	³ H-Spiroperidol bindings	
		ED50(ip) (μ mol/kg)	ED50(po) (μ mol/kg)		ED50(sc) (μ mol/kg)	5-HT ₂ $IC_{50}/10^{-9}M$
		1-6h	24h			
Lu 23-155	3.8*					
Lu 23-156	0.07*	<0.19*	1.1*	0.03	19	15
Lu 23-157	0.37*	0.49*	2.6*	0.12		
Lu 23-158	2.9*			0.11		
Lu 23-159	47*					
Lu 23-160	3.4*		5.2*		11	34
Lu 23-161	0.05*	0.09*	0.18*			
Lu 23-162	1.7*					
Lu 23-163	1.1*					
Lu 23-167	2.7*	2.7*	>11.0*			
Lu 23-171	0.11*					
Lu 23-172	>70*			>0.55	31	
Lu 23-173	0.77*	1.8*		>7.1	42	60
Lu 23-174	>72*			0.49	20	6.6
Lu 23-175	0.32*	0.68*			11	6.7
Lu 24-001	2.6			0.19		8.8
Lu 24-002	0.45*			>0.45		
Lu 24-003	0.09*				6.0	14
Lu 24-004	1.1*					
Lu 24-012	>20*					
Lu 24-013	>20*					
Lu 24-014	>22*					
Lu 24-015	3.8*					
Lu 24-016	>30*					
Lu 24-022						
Lu 24-024						
Clorpromazine	23	70		0.38	24	30
(+/-)Lupentaxol	0.14	2.4	19	0.042	3.2	13
Haloperidol	0.11	1.0		0.99	8.2	48
Levodopa	0.06	0.61	0.9	0.06	19	8.6

86292965

1577

ED50 from sc administration

LD₅₀ i.v. in mice was determined for Lu 21-152 and Lu 22-135 to be 147 $\mu\text{mol}/\text{kg}$ and 276 $\mu\text{mol}/\text{kg}$ respectively which indicates a comparatively low acute toxicity as compared with known neuroleptics such as chlorpromazine, cis(Z)-flupentixol and tefludazin having values between 120-180 $\mu\text{mol}/\text{kg}$.

5 The compounds of Formula I and the non-toxic acid addition salts thereof may be administered to animals such as dogs, cats, horses, sheeps or the like, including human beings, both orally and parenterally, and may be used for example in the form of tablets, capsules, powders, syrups or in the form of the usual sterile solutions for injection. - Results upon administration to human beings have been
10 very gratifying.

Most conveniently the compounds of Formula I are administered orally in unit dosage form such as tablets or capsules, each dosage unit containing the free amine or a non-toxic acid addition salt of one of the said compounds in an amount of from about 0.10 to about 100 mg, more preferably, however, from about 5 to
15 50 mg, calculated as the free amine, the total daily dosage usually ranging from about 1.0 to about 500 mg. The exact individual dosages as well as daily dosages in a particular case will, of course, be determined according to established medical principles under the direction of a physician.

When preparing tablets, the active ingredient is for the most part mixed with
20 ordinary tablet adjuvants such as corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, or the like.

When the compound of Formula I is an ester, preferably a decanoic acid ester, palmitic acid ester or a behenic acid ester, the composition may advantageously be an oily solution for injection, and such solutions often have a very prolonged effect when compared with the corresponding unesterified compound.

1578

86292965

22

Typical examples of formulas for composition containing 1-(4'fluorophenyl)-3-(4-(2-hydroxyethyl-1-piperazinyl)-5-trifluoromethylindole (called Lu 21-152 for short) as the active ingredient, are as follows:

5 1) Tablets containing 5 milligrams of Lu 21-152
calculated as the free base:

	Lu 21-152	5 mg
	Lactose	18 mg
	Potato starch	27 mg
	Saccharose	58 mg
10	Sorbitol	3 mg
	Talcum	5 mg
	Gelatine	2 mg
	Povidone	1 mg
	Magnesium stearate	0.5 mg

15 2) Tablets containing 50 milligrams of Lu 21-152
calculated as the free base:

	Lu 21-152	50 mg
	Lactose	16 mg
	Potato starch	45 mg
20	Saccharose	106 mg
	Sorbitol	6 mg
	Talcum	9 mg
	Gelatine	4 mg
	Povidone	3 mg
25	Magnesium stearate	0.6 mg

86292965

30 3) Syrup containing per milliliter:

	Lu 21-152	10 mg
	Sorbitol	500 mg
	Tragacanth	7 mg
	Glycerol	50 mg
30	Methyl-paraben	1 mg
	Propyl-paraben	0.1 mg
	Ethanol	6.605 ml

4) Solution for injection containing per milliliter:

Lu 21-152	50 mg
Acetic acid	17.9 mg
Sterile water	ad 1 ml

5) Solution for injection containing per milliliter:

Lu 21-152	10 mg
Sorbitol	42.9 mg
Acetic acid	0.63 mg
Sodium hydroxide	22 mg
Sterile water	ad 1 ml

10

Any other pharmaceutical tableting adjuvants may be used provided that they are compatible with the active ingredient, and additional compositions and dosage forms may be similar to those presently used for neuroleptics, such as chlorpenthixol, flupentixol or fluphenazine.

15 Also combinations of the compounds of Formula I as well as their non-toxic acid salts with other active ingredients, especially other neuroleptics, thymoleptics, tranquilizers, analgetics or the like, will within the scope of the present invention.

20 As previously stated, when isolating the compounds of Formula I in the form of an acid addition salt the acid is preferably selected so as to contain an anion which is non-toxic and pharmacologically acceptable, at least in usual therapeutic doses. Representative salts which are included in this preferred group are the hydrochlorides, hydrobromides, sulphates, acetates, phosphates, nitrates, methanesulphonates, ethane-sulphonates, lactates, citrates, tartrates or bitartrates, pamoates and maleates of the amines of Formula I. Other acids are 25 likewise suitable and may be employed if desired. For example: fumaric, benzoic, ascorbic, succinic, salicylic, bismethylenesalicylic, propionic, gluconic, malic, malonic, mandelic, canonic, citraconic, stearic, palmitic, itaconic, glycolic, benzenesulphonic, and sulphamic acids may also be employed as acid addition 30 saltforming acids.

86292965

1580

24

0200322

When it is desired to isolate a compound of the invention in the form of the free base, this may be done according to conventional procedure as by dissolving the isolated or unisolated salt in water, treating with a suitable alkaline material, extracting the liberated free base with a suitable organic solvent drying the extract and evaporating to dryness or fractionally distilling to effect isolation of the free basic amine.


The invention also comprises a method for the alleviation, palliation, mitigation or inhibition of the manifestations of certain physiological-psychological abnormalities of animals, including psychoses, by administering to a living animal body, including human beings, an adequate quantity of a compound of Formula I or a non-toxic acid addition salt thereof. An adequate quantity would be from about 0.001 mg to about 10 mg per kg of body weight in each unit dosage, and from about 0.003 milligrams to about 7 milligrams /kg of body weight per day.

It is to be understood that the invention is not limited to the exact details of operation or exact compound or compositions shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art.

86292965

1581

Indole derivatives of the following general formula:




wherein R is phenyl, optionally substituted with halogen, lower alkyl or trifluoromethyl, or a hetero aromatic group, such as 2-thienyl, 3-thienyl, 2-furoyl, 3-furoyl, 2-thiazol, 2-oxazol, 2-imidazole, 2-pyridyl, 3-pyridyl or 4-pyridyl; R^1 is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, lower alkylthio, trifluoromethyl, lower alkylsulfonyl, amino, lower alkylamino or lower di-alkylamino;

" A " is nitrogen or carbon, and the dotted line indicates - when A is carbon - an optional bond;

R^2 is hydrogen, cycloalkyl, lower alkyl or lower alkenyl, optionally substituted with one or two hydroxy groups, any hydroxy group present being optionally esterified with an aliphatic carboxylic acid radical having from two to twenty-four carbon atoms inclusive,

or R^2 is the group



wherein "n" is an integer of 2-6;

X is oxygen or sulfur, or $>C=X$ may constitute the group $\backslash CH=$ when Y is $=N-$ or $=CH-$;

Y is oxygen, sulfur, CH_2 or $N R^3$, where R^3 is hydrogen or lower alkyl, lower alkenyl or a cycloalkylmethyl group, said "cycloalkyl" having from three to six carbon atoms inclusive;

Z is $-(CH_2)_m-$, "m" being 2 or 3, or Z is $-CH=CH-$ or 1,2-phenylene optionally substituted with halogen or trifluoromethyl, or Z is $-CO(or S)CH_2-$;

U is nitrogen or carbon,

provided that when R^1 is chloro, A is nitrogen and R^2 is methyl or cyclohexyl, R may not be phenyl;

as well as their pharmaceutically acceptable acid addition salts.

26

-2-

1 An indole derivative of Claim 1, wherein R¹ is chlorine, fluorine, trifluoromethyl,
2 methyl, nitro or amino in the 5-position, R is phenyl substituted with fluorine
3 in the 4'- or 2'-position, R² is methyl, 2-hydroxyethyl or 3-hydroxypropyl,
4 and A is as defined in Claim 1.

-3-

1 1-(4'-Fluorophenyl)-3-(4-(2-hydroxyethyl)-piperazino)-5-trifluoromethyl-
2 1H-indole.

3 1-(4'-Fluorophenyl)-5-nitro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-
4 1H-indole.

5 5-Chloro-1-(4'-fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-
6 1H-indole.

7 1-(4'-Fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-
8 5-nitro-1H-indole.

9 1-(4'-Fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-
10 5-trifluoromethyl-1H-indole.


11 5-Fluoro-1-(4'-fluorophenyl)-3-(1-(3-hydroxypropyl)-1,2,3,6-tetrahydropyridin-
12 4-yl)-1H-indole

13 as well as pharmaceutically acceptable acid addition salts thereof.

1583

86292965

1 A method for the preparation of an indole derivative of the following general
2 formula:




4 wherein R is phenyl, optionally substituted with halogen, lower alkyl or trifluoro-
5 methyl, or a hetero aromatic group, such as 2-thienyl, 3-thienyl, 2-furoyl, 3-
6 furoyl, 2-thiazol, 2-oxazol, 2-imidazole, 2-pyridyl, 3-pyridyl or 4-pyridyl;

7 R¹ is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, lower
8 alkylthio, trifluoromethyl, lower alkylsulfonyl, amino, lower alkylamino or lower
9 di-alkylamino;

10 "A" is nitrogen or carbon, and the dotted line indicates - when A is carbon - an
11 optional bond;

12 R² is hydrogen, cycloalkyl, lower alkyl or lower alkenyl, optionally substituted
13 with one or two hydroxy groups, any hydroxy group present being optionally
14 esterified with an aliphatic carboxylic acid radical having from two to twenty-
15 four carbon atoms inclusive,

16 or R² is the group



18 wherein "n" is an integer of 2-6;

19 X is oxygen or sulfur, or >C=X may constitute the group >CH= when Y is
20 >N- or >CH-;

21 Y is oxygen, sulfur, CH₂ or N R³, where R³ is hydrogen or lower alkyl, lower
22 alkenyl or a cycloalkylmethyl group, said "cycloalkyl" having from three to six
23 carbon atoms inclusive;

24 Z is -(CH₂)_m-, "m" being 2 or 3, or Z is -CH=CH- or 1,2-phenylene optionally
25 substituted with halogen or trifluoromethyl, or Z is -CO(or S)CH₂-;


26 U is nitrogen or carbon,

27 provided that when R¹ is chloro, A is nitrogen and R² is
28 methyl or cyclohexyl, R may not be phenyl
29 as well as their pharmaceutically acceptable acid addition salts,


30 which comprises

0200322

31 a) reacting an indole derivative of the following formula:




33 wherein R¹ and R are as defined above, with a 4-piperidone of the formula:



35 wherein R² is as defined above,

36 or


37 b) reducing a compound of the following formula:



39 wherein R¹, R and R² are as defined above,

40 or

41 c) reacting a compound of the following formula:



43 wherein R¹, R² and A are as defined above, with a compound of formula:

44 R-hal

45 wherein R is as defined above and "hal" is halogen, in the presence of a metal


46 f51851

86292965

47

d) reacting a compound of the following formula:

48



49

50


wherein R¹, R and A are as defined above, with a lower alkyl halide or an epoxide of formula $\text{H}_2\text{C}-\text{CH R}$ wherein R is hydrogen, methyl or ethyl,

or

51

e) reducing a compound of the following formula:

52



53

54


wherein R¹, R and A are as defined above and R⁴ is hydrogen, lower alkyl (1-3 C-atoms) or lower alkoxy (1-3 C-atoms),

or

55

f) heating a compound of the following formula:

56



57

wherein R¹ and R are as defined above, with a piperazine of formula:

58


59

wherein R² is as defined above,

or

1588

86292965




30

0200322

60 g) reducing a compound of the following formula:

61



VIII

62 wherein R¹, R and R² are as defined above, with a suitable reducing agent,
 63 whereupon the indole of Formula I is isolated in the form of the free base or a
 64 pharmaceutically acceptable acid addition salt thereof, and if the group R²
 65 contains one or two hydroxyl groups, if desired, acylating such a hydroxy group
 66 with a reactive derivative of an aliphatic carboxylic acid having from two to
 67 twenty-four carbon atoms, and isolating the ester formed as the free base or a
 68 pharmaceutically acceptable acid addition salt thereof.

-5-

1 A method according to Claim 4 wherein R¹ is chlorine, fluorine, trifluoromethyl,
 2 methyl, nitro or amino in the 5-position, R is phenyl substituted with fluorine
 3 in the 4'- or the 2'-position, R² is methyl, 2-hydroxyethyl or 3-hydroxypropyl,
 4 and A is as defined in Claim 4.

-6-

1 A method according to Claim 4 or 5 for the preparation of the following
 2 compounds:

3 1-(4'-Fluorophenyl)-3-(4-(2-hydroxyethyl)-piperazino)-5-trifluoromethyl-
 4 1H-indole.

5 1-(4'-Fluorophenyl)-5-nitro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-
 6 1H-indole.

7 5-Chloro-1-(4'-fluorophenyl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-
 8 1H-indole.

1587

86292965

1 9 1-(4'-Fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-
10 5-nitro-1H-indole.

11 1-(4'-Fluorophenyl)-3-(1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl)-
12 5-trifluoromethyl-1H-indole.

13 5-Fluoro-1-(4'-fluorophenyl)-3-(1-(3-hydroxypropyl)-1,2,3,6-tetrahydropyridin-
14 4-yl)-1H-indole

15 as well as pharmaceutically acceptable acid addition salts thereof.

-7-

1 A pharmaceutical composition in unit dosage form comprising - as an active
2 ingredient - a compound as defined in Claim 1, and one or more pharmaceutical
3 diluents or carriers.

-8-

1 A pharmaceutical composition in unit dosage form, according to Claim 7,
2 wherein the active ingredient is present in an amount from 0.10 to 100 milligrams
3 per unit dosage.

-9-

1 A pharmaceutical composition in unit dosage form, according to Claim 7
2 or 8, wherein the active ingredient is selected from the compounds of Claim
3.

1588

86292965



European Patent
Office

EUROPEAN SEARCH REPORT

0200322

Application number:

EP 86 30 1989

DOCUMENTS CONSIDERED TO BE RELEVANT

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Description of document with indication where appropriate of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
A	FR-A-2 227 873 (C.H. BOEHRINGER) * Pages 1,4 *	1-9	C 07 D 209/40 C 07 D 401/14 C 07 D 413/14 A 61 K 31/40
A	EP-A-0 112 191 (ROUSSEL-UCLAF) * Claims *	1-9	
D, A	EP-A-0 022 705 (ROUSSEL-UCLAF) * Summary; claims *	1-9	
A	EP-A-0 003 199 (ROUSSEL-UCLAF) * Claims *	1-9	
A	EP-A-0 003 200 (ROUSSEL-UCLAF) * Claims *	1-9	
	-----		TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 07 D 401/00 C 07 D 413/00 C 07 D 209/00

86292965

1589

The present search report has been drawn up for all claims

Place of search THE HAGUE	Date of completion of the search 11-08-1986	Examiner MAISONNEUVE J.A.
------------------------------	--	------------------------------

CATEGORY OF CITED DOCUMENTS

- X particularly relevant if taken alone
- Y particularly relevant if combined with another document of the same category
- A technological background
- O non-written disclosure
- P intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or
after the filing date
D : document cited in the application
L : document cited for other reasons
A : member of the same patent family, corresponding
document